Research Papers:

MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma

Xudong Zhang, Weiguo Ji, Ruixia Huang, Lifeng Li, Xinhua Wang, Ling Li, Xiaorui Fu, Zhenchang Sun, Zhaoming Li, Qingjiang Chen and Mingzhi Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:53808-53819. https://doi.org/10.18632/oncotarget.10780

Metrics: PDF 1374 views  |   HTML 1697 views  |   ?  


Xudong Zhang1,*, Weiguo Ji2,*, Ruixia Huang1, Lifeng Li1, Xinhua Wang1, Ling Li1, Xiaorui Fu1, Zhenchang Sun1, Zhaoming Li1, Qingjiang Chen1, Mingzhi Zhang3

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China

2Department of Oncology, Third Affiliated Hospital of Henan College of Traditional Chinese Medicine, Zhengzhou 450008, China

3Department of Oncology, Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450008, China

*These authors contributed equally to this manuscript and should be considered as co-first authors

Correspondence to:

Mingzhi Zhang, email: mingzhi_zhang1@126.com

Keywords: natural killer/T-cell lymphoma, Solexa high-throughput sequencing, miRNA, miRNA-155

Received: February 05, 2016    Accepted: July 09, 2016    Published: July 22, 2016


Natural killer/T-cell lymphoma (NKTCL) is characterized by its highly aggressive nature and rapid progression. MicroRNAs (miRNAs) play key roles in the development of NKTCL. We utilized next-generation Solexa high-throughput sequencing to compare miRNA expression in the SNK-6 and YTS NKTCL cell lines with expression in normal NK cells. We found that 195 miRNAs were upregulated in the SNK-6 cells and 286 miRNAs were upregulated in the YTS cells. Based on those results, we selected six miRNAs, including miRNA-155, and confirmed their expression using real-time polymerase chain reaction. Expression of miRNA-155 was higher in SNK-6 and YKS cells than in normal NK cells. We next determined the levels of miRNA-155 in the serum of healthy individuals and NKTCL patients, and correlated its expression with clinical parameters and inflammatory factors detected using enzyme-linked immunoabsorbent assays. Levels of miRNA-155 were higher in NKTCL patients’ serum than in serum from healthy individuals. miRNA-155 expression was higher in patients with stable or progressive disease (SD+PD) than in those with partial or complete remission (PR+CR). While further studies are needed to clarify the underlying molecular mechanisms, it appears miRNA-155 may be a molecular marker of NKTCL.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10780